A novel mouse model for phenytoin-induced liver injury: Involvement of immune-related factors and P450-mediated metabolism

Toxicological Sciences

Volumn 136, Issue 1, 2013, Pages 250-263

  Sasaki, Eita ^a   Matsuo, Kentaro ^a   Iida, Azumi ^a   Tsuneyama, Koichi ^b   Fukami, Tatsuki ^a   Nakajima, Miki ^a   Yokoi, Tsuyoshi ^a,c  

^a KANAZAWA UNIVERSITY   (Japan)

^b UNIVERSITY OF TOYAMA   (Japan)

^c NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Glutathione; Hepatotoxicity; IL 17; Mouse model.; Phenytoin

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIBODY; CYTOCHROME P450; GLUTATHIONE; INTERLEUKIN 1BETA; MESSENGER RNA; PHENYTOIN; PROSTAGLANDIN E1;

AEROBIC METABOLISM; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; FEMALE; INNATE IMMUNITY; LIVER LEVEL; MALE; MOUSE; NONHUMAN; OXIDATIVE STRESS; TOXIC HEPATITIS;

GLUTATHIONE; HEPATOTOXICITY; IL-17; MOUSE MODEL.; PHENYTOIN;

ANIMALS; BUTHIONINE SULFOXIMINE; CYTOCHROME P-450 ENZYME SYSTEM; CYTOPROTECTION; DISEASE MODELS, ANIMAL; DRUG-INDUCED LIVER INJURY; ENZYME INHIBITORS; FEMALE; GLUTATHIONE; IMMUNITY, INNATE; INFLAMMASOMES; INFLAMMATION MEDIATORS; LIVER; MICE; MICE, INBRED C57BL; NECROSIS; OXIDATIVE STRESS; PHENYTOIN; T-LYMPHOCYTES, HELPER-INDUCER;

EID: 84887883101     PISSN: 10966080     EISSN: 10960929     Source Type: Journal    
DOI: 10.1093/toxsci/kft184     Document Type: Article

References (41)

1. Acosta-Rodriguez, E. V., Napolitani, G., Lanzavecchia, A., and Sallusto, F. (2007). Interleukins 1beta and 6 but not transforming growth factor-beta are essential for the differentiation of interleukin 17-producing human T helper cells. Nat. Immunol. 8, 942-949.
2. Bianchi, M. E. (2007). DAMPs, PAMPs and alarmins: All we need to know about danger. J. Leukoc. Biol. 81, 1-5.
3. Bryant, C., and Fitzgerald, K. A. (2009). Molecular mechanisms involved in inflammasome activation. Trends Cell Biol. 19, 455-464.
4. Chaudhry, A. S., Urban, T. J., Lamba, J. K., Birnbaum, A. K., Remmel, R. P., Subramanian, M., Strom, S., You, J. H., Kasperaviciute, D., Catarino, C. B., et al. (2010). CYP2C9*1B promoter polymorphisms, in linkage with CYP2C19*2, affect phenytoin autoinduction of clearance and maintenance dose. J. Pharmacol. Exp. Ther. 332, 599-611.
5. Cuttle, L., Munns, A. J., Hogg, N. A., Scott, J. R., Hooper, W. D., Dickinson, R. G., and Gillam, E. M. (2000). Phenytoin metabolism by human cytochrome P450: involvement of P450 3A and 2C forms in secondary metabolism and drug-protein adduct formation. Drug Metab. Dispos. 28, 945-950.
6. Dhar, G. J., Pierach, C. A., Ahamed, P. N., and Howard, R. B. (1974). Diphenylhydantoin-induced hepatic necrosis. Postgrad. Med. 56, 128-134.
7. Drew, R., and Miners, J. O. (1984). The effects of buthionine sulphoximine (BSO) on glutathione depletion and xenobiotic biotransformation. Biochem. Pharmacol. 33, 2989-2994.
8. Fleishaker, J. C., Pearson, L. K., and Peters, G. R. (1995). Phenytoin causes a rapid increase in 6 beta-hydroxycortisol urinary excretion in humans-A putative measure of CYP3A induction. J. Pharm. Sci. 84, 292-294.
9. Griffith, O. W., and Meister, A. (1979). Potent and specific inhibition of glutathione synthesis by buthionine sulfoximine (S-n-butyl homocysteine sulfoximine). J. Biol. Chem. 254, 7558-7560.
10. Hagemeyer, C. E., Bürck, C., Schwab, R., Knoth, R., and Meyer, R. P. (2010). 7-Benzyloxyresorufin-O-dealkylase activity as a marker for measuring cytochrome P450 CYP3A induction in mouse liver. Anal. Biochem. 398, 104-111.
11. Haruda, F. (1979). Phenytoin hypersensitivity: 38 cases. Neurology 29, 1480-1485.
12. Higuchi, S., Yano, A., Takai, S., Tsuneyama, K., Fukami, T., Nakajima, M., and Yokoi, T. (2012). Metabolic activation and inflammation reactions involved in carbamazepine-induced liver injury. Toxicol. Sci. 130, 4-16.
13. Kidd, P. (2003). Th1/Th2 balance: The hypothesis, its limitations, and implications for health and disease. Altern. Med. Rev. 8, 223-246.
14. Kita, H., Mackay, I. R., Van De Water, J., and Gershwin, M. E. (2001). The lymphoid liver: Considerations on pathways to autoimmune injury. Gastroenterology 120, 1485-1501.
15. Kobayashi, E., Kobayashi, M., Tsuneyama, K., Fukami, T., Nakajima, M., and Yokoi, T. (2009). Halothane-induced liver injury is mediated by interleukin-17 in mice. Toxicol. Sci. 111, 302-310.
16. Kobayashi, M., Higuchi, S., Ide, M., Nishikawa, S., Fukami, T., Nakajima, M., and Yokoi, T. (2012). Th2 cytokine-mediated methimazole-induced acute liver injury in mice. J. Appl. Toxicol. 32, 823-833.
17. Langrish, C. L., Chen, Y., Blumenschein, W. M., Mattson, J., Basham, B., Sedgwick, J. D., McClanahan, T., Kastelein, R. A., and Cua, D. J. (2005). IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J. Exp. Med. 201, 233-240.
18. Latz, E. (2010). The inflammasomes: Mechanisms of activation and function. Curr. Opin. Immunol. 22, 28-33.
19. Martinon, F., Mayor, A., and Tschopp, J. (2009). The inflammasomes: Guardians of the body. Annu. Rev. Immunol. 27, 229-265.
20. Mullick, F. G., and Ishak, K. G. (1980). Hepatic injury associated with diphenylhydantoin therapy. A clinicopathologic study of 20 cases. Am. J. Clin. Pathol. 74, 442-452.
21. Munns, A. J., De Voss, J. J., Hooper, W. D., Dickinson, R. G., and Gillam, E. M. (1997). Bioactivation of phenytoin by human cytochrome P450: Characterization of the mechanism and targets of covalent adduct formation. Chem. Res. Toxicol. 10, 1049-1058.
22. Ong, M. M., Wang, A. S., Leow, K. Y., Khoo, Y. M., and Boelsterli, U. A. (2006). Nimesulide-induced hepatic mitochondrial injury in heterozygous Sod2(+/-) mice. Free Radic. Biol. Med. 40, 420-429.
23. Oo, Y. H., and Adams, D. H. (2010). The role of chemokines in the recruitment of lymphocytes to the liver. J. Autoimmun. 34, 45-54.
24. Roy, D., and Snodgrass, W. R. (1990). Covalent binding of phenytoin to protein and modulation of phenytoin metabolism by thiols in A/J mouse liver microsomes. J. Pharmacol. Exp. Ther. 252, 895-900.
25. Scaffidi, P., Misteli, T., and Bianchi, M. E. (2002). Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 418, 191-195.
26. Schroder, K., and Tschopp, J. (2010). The inflammasomes. Cell 140, 821-832.
27. Schwabe, R. F., Seki, E., and Brenner, D. A. (2006). Toll-like receptor signaling in the liver. Gastroenterology 130, 1886-1900.
28. Shaw, P. J., Ditewig, A. C., Waring, J. F., Liguori, M. J., Blomme, E. A., Ganey, P. E., and Roth, R. A. (2009). Coexposure of mice to trovafloxacin and lipopolysaccharide, a model of idiosyncratic hepatotoxicity, results in a unique gene expression profile and interferon gamma-dependent liver injury. Toxicol. Sci. 107, 270-280.
29. Shimizu, S., Atsumi, R., Itokawa, K., Iwasaki, M., Aoki, T., Ono, C., Izumi, T., Sudo, K., and Okazaki, O. (2009). Metabolism-dependent hepatotoxicity of amodiaquine in glutathione-depleted mice. Arch. Toxicol. 83, 701-707.
30. Shimizu, S., Atsumi, R., Nakazawa, T., Izumi, T., Sudo, K., Okazaki, O., and Saji, H. (2011). Ticlopidine-induced hepatotoxicity in a GSH-depleted rat model. Arch. Toxicol. 85, 347-353.
31. Spielberg, S. P., Gordon, G. B., Blake, D. A., Goldstein, D. A., and Herlong, H. F. (1981). Predisposition to phenytoin hepatotoxicity assessed in vitro. N. Engl. J. Med. 305, 722-727.
32. Steinman, L. (2007). A brief history of T(H)17, the first major revision in the T(H)1/ T(H)2 hypothesis of T cell-mediated tissue damage. Nat. Med. 13, 139-145.
33. Talpain, E., Armstrong, R. A., Coleman, R. A., and Vardey, C. J. (1995). Characterization of the PGE receptor subtype mediating inhibition of superoxide production in human neutrophils. Br. J. Pharmacol. 114, 1459-1465.
34. Taylor, J. W., Stein, M. N., Murphy, M. J., and Mitros, F. A. (1984). Cholestatic liver dysfunction after long-term phenytoin therapy. Arch. Neurol. 41, 500-501.
35. Tietze, F. (1969). Enzymic method for quantitative determination of nanogram amounts of total and oxidized glutathione: Applications to mammalian blood and other tissues. Anal. Biochem. 27, 502-522.
36. Watanabe, T., Sagisaka, H., Arakawa, S., Shibaya, Y., Watanabe, M., Igarashi, I., Tanaka, K., Totsuka, S., Takasaki, W., and Manabe, S. (2003). A novel model of continuous depletion of glutathione in mice treated with l-buthionine (S,R)-sulfoximine. J. Toxicol. Sci. 28, 455-469.
37. Winn, L. M., and Wells, P. G. (1995). Phenytoin-initiated DNA oxidation in murine embryo culture, and embryo protection by the antioxidative enzymes superoxide dismutase and catalase: Evidence for reactive oxygen speciesmediated DNA oxidation in the molecular mechanism of phenytoin teratogenicity. Mol. Pharmacol. 48, 112-120.
38. Winn, L. M., and Wells, P. G. (1999). Maternal administration of superoxide dismutase and catalase in phenytoin teratogenicity. Free Radic. Biol. Med. 26, 266-274.
39. Yamazaki, H., Komatsu, T., Takemoto, K., Saeki, M., Minami, Y., Kawaguchi, Y., Shimada, N., Nakajima, M., and Yokoi, T. (2001). Decreases in phenytoin hydroxylation activities catalyzed by liver microsomal cytochrome P450 enzymes in phenytoin-treated rats. Drug Metab. Dispos. 29, 427-434.
40. Zhou, R., Tardivel, A., Thorens, B., Choi, I., and Tschopp, J. (2010). Thioredoxin-interacting protein links oxidative stress to inflammasome activation. Nat. Immunol. 11, 136-140.
41. Zimmerman, H. J. (1999). Hepatotoxicity: The Adverse Effects of Drugs and Other Chemicals on the Liver. Lippncott Williams & Wilkins, Philadelphia, PA.